Vericel Corp

Common Name
Vericel
Country
United States
Sector
Healthcare
Industry
Biotechnology
Employees
357
Ticker
VCEL
Exchange
NASDAQ/NMS
Website
vcel.com
Description
Vericel Corporation is a biopharmaceutical company focused on the development and commercialization of innovative cellular therapies for patients with severe diseases and conditions. The company's pri...

Vericel's Financial Statements Preview

Below are the financial statements of Vericel, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Interested in getting early access to our real-time standardized financial datafeed?
Learn More
All figures in millions of USD
2024
2023
2022
Product sales, net
237.22a
197.52a
163.7a
Other revenue
0a
0a
0.67a
Total revenue
237.22a
197.52a
164.37a
Cost of product sales
-65.12a
-61.94a
-54.58a
Gross profit
172.11a
135.58a
109.79a
Research and development
-24.8a
-21.04a
-19.94a
Selling, general and administrative
-142.79a
-121a
-106.9a
Total operating expenses
-167.59a
-142.04a
-126.85a
Income (loss) from operations
4.52a
-6.46a
-17.06a
Other income (expense)
Interest income
6.41a
4.63a
1.34a
Interest expense
-0.61a
-0.6a
-0.37a
Other income
0.2a
0.06a
0.1a
Total other income
5.99a
4.1a
1.07a
Income (loss) before income taxes
10.51a
-2.37a
-15.99a
Income tax expense
-0.15a
-0.81a
-0.72a
Net income (loss)
10.36a
-3.18a
-16.71a
Download Data

Verified Sources Behind Vericel’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Vericel’s data sources below and access millions more through our Disclosure Search.

a. Vericel's 10-K 2024
a. Vericel's 10-K 2024
Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

Tracenable is building real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?